Ponte, L., Jerome, L., Hamilton, S., Mithoefer, M.C., Yazar-Klosinski, B.B., Vermetten, E. and Feduccia, A.A. (2021)

Wang, J. B., Lin, J., Bedrosian, L., Coker, A., Jerome, I., Feduccia, A., Lilienstein, A., Harrison, C., Heimler, E., Mithoefer, M., Mithoefer, A., Ot’alora G., M., Poulter, B., Carlin, S., Matthews, R., Yazar-Klosinski, B., Emerson, A., & Doblin, R. (2021)

Jerome, L., Feduccia, A. A., Wang, J. B., Hamilton, S., Yazar-Klosinski, B., Emerson, A., Mithoefer, M. C., & Doblin, R. (2020)

The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSD

Marseille, E., Kahn, J. G., Yazar-Klosinski, B., & Doblin, R. (2020)

Discontinuation of medications classified as reuptake inhibitors affects treatment response of MDMA-assisted psychotherapy

Feduccia, A. A., Jerome, L., Mithoefer, M. C., & Holland, J. (2020)

MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study.

Wolfson, P. E., Andries, J., Feduccia, A. A., Jerome, L., Wang, J. B., Williams, E., … & Emerson, A. (2020)

Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments.

Greenway, K. T., Garel, N., Jerome, L., & Feduccia, A. A. (2020)

MDMA-facilitated cognitive-behavioural conjoint therapy for posttraumatic stress disorder: an uncontrolled trial

Candice M. Monson, Anne C. Wagner, Ann T. Mithoefer, Rachel E. Liebman, Allison A. Feduccia, Lisa Jerome, Berra Yazar-Klosinski, Amy Emerson, Rick Doblin & Michael C. Mithoefer (2020)

Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline.

Feduccia, A.A., Jerome, L., Mithoefer, A., Yazar-Klosinski, B., Emerson, A., Doblin, R. (2019)

The past and future of psychedelic science: an introduction to this issue.

Doblin, R. E., Christiansen, M., Jerome, L., & Burge, B. (2019)

MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials

Mithoefer, M.C., Feduccia, A.A., Jerome, L., Mithoefer, A., Wagner, M., Walsh, Z., Hamilton, S., Yazar-Klosinski, B., Emerson, A., Doblin, R. (2019)

3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial.

Ot’alora, G, M., Grigsby, J., Poulter, B., Van Derveer, J. W., Giron, S. G., Jerome, L., Feduccia, A., Hamilton, S., Yazar-Klosinski, B., Emerson, A., Mithoefer, M., Doblin, R. (2018)

Reduction in Social Anxiety After MDMA-Assisted Psychotherapy with Autistic Adults: A Randomized, Double-blind, Placebo-Controlled Pilot Study.

Danforth, A.L., Grob, C.S., Struble, C., Feduccia, A.A., Walker, N., Jerome, L., Yazar-Klosinski, B., Emerson, A. (2018)

3,4-Methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy for Post-Traumatic Stress Disorder in Military Veterans, Firefighters, and Police Officers: A Randomised, Double-Blind, Dose-Response, Phase 2 Clinical Trial.

Mithoefer, M. C., Mithoefer, Mithoefer, A. T., Feduccia, A. A., Jerome, L., Wagner, M., Wymer, J., Holland, J., Hamilton, S., Yazar-Klosinski, B., Emerson, A., Doblin, R. (2018)

Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study

Noller, G, Frampton, C, Yazar-Klosinski, B (2017)

Potential Psychiatric Uses for MDMA.

Yazar‐Klosinski, B., Mithoefer, M. (2017)

MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults.

Danforth A, Struble C, Yazar-Klosinski B, Grob C (2016)

Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases

Gasser P, Holstein D, Michel Y, Doblin R, Yazar-Klosinski B, Passie T, Brenneisen R (2014)

Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study​.

Mithoefer M, Wagner M, Mithoefer A, Jerome L, Martin S, Yazar-Klosinski B, Michel Y, Brewerton T, Doblin R (2013)

Can MDMA Play a Role in the Treatment of Substance Abuse?

Jerome L, Schuster S, Yazar-Klosinski B (2013)

The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study.

Mithoefer M, Wagner M, Mithoefer A, Jerome L, Doblin R (2010)

The varieties of ecstatic experience: an exploration of the subjective experiences of ecstasy.

Sumnall H, Cole J, Jerome L (2006)

The effects of stereotype threat on cognitive function in ecstasy users.

Cole, J. C., Michailidou, K., Jerome, L., & Sumnall, H. R. (2006)

MAPS Public Benefit Corporation

Our Mission
Who We Are
Contact Us

3141 Stevens Creek Blvd #40547
San Jose, CA 95117

Therapy Training


MAPS PBC is a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS). MAPS is a 501(c)(3) non-profit research and educational organization.

Stay Up-to-Date about MDMA Therapy Training

You have Successfully Subscribed!